SIGMAR1 and COVID-19: There are hypotheses about fluvoxamine that may show the mechanism of its action in COVID-19 and sepsis, including anti-inflammatory effects (reduction of cytokines) induced by Sig-1R activation and modulation of the impact of IRE1 on autophagy and inhibition of platelet activation by SSRIs and direct antiviral effects Through lysosomotropic properties (Schlienger and Meier, 2003; Fung and Liu, 2019; Homolak and Kodvanj, 2020).